Alzheimer’s Brain Damage May Start in the Neck

Alzheimer’s disease does its damage inside the brain, but according to a new mouse study, part of the plan may be drawn up somewhere else entirely: the lymph nodes in the neck.

Researchers at Washington University School of Medicine in St. Louis report that the T cells that infiltrate the brain and drive tau-related neurodegeneration are primed by a rare class of dendritic cells stationed outside the brain, in the lymph nodes that drain it, rather than by anything happening in brain tissue itself. When the team genetically removed those dendritic cells from tau-transgenic mice from birth, the brain-invading T cells lost their instructions: brain shrinkage eased, nest-building behavior, a rough proxy for cognitive health in mice, recovered, and markers of neuronal damage fell. It is a finding that moves the target for a future treatment from behind the blood-brain barrier to somewhere a needle can actually reach.

T cells, especially those marked CD8 (built to kill infected or damaged cells), have been turning up in the brains of people with Alzheimer’s disease and other tauopathies for years, in numbers that track how much tau pathology has built up. What nobody had pinned down was where those T cells get their marching orders, or how they end up targeting brain tissue in the first place.

The Messengers Nobody Finds in the Brain

The likely dispatcher is a dendritic cell subtype called cDC1, a scarce immune cell, accounting for only approximately 0.4 to 0.6 percent of the immune cells the researchers sampled, that specializes in a trick called cross-presentation: chewing up material from outside its own body and displaying pieces of it to CD8 T cells like a most-wanted poster. cDC1s are almost never found in brain tissue itself, even in mice with severe brain atrophy, which is what first pointed the researchers toward the lymph nodes rather than the brain as the scene of the crime. The team deleted cDC1s with a targeted genetic knockout, using a molecular switch specific to that one cell type, in mice bred to carry both a mutant human tau gene and APOE4 (a gene variant that raises Alzheimer’s risk), a combination the researchers call TE4 (their shorthand for this tau-and-APOE4 cross). Those cDC1-deficient TE4 mice were compared against tau-carrying littermates that kept their cDC1s intact.

The results were stark. T cells in the brains of the cDC1-deficient mice dropped by roughly half, and CD8 T cells specifically, the subset previously shown to drive damage, fell even further, while the hippocampus, the memory-critical structure hit hardest by tau pathology, kept its neurons largely intact.

Losing cDC1s did not touch the underlying tau pathology; tangle levels looked essentially the same between the two groups of mice, so the protection was not coming from cleaner tau, it was coming from a defanged immune response. Microglia, the brain’s resident cleanup crews, and astrocytes calmed down too, with lower levels of several activation markers in the cDC1-deficient animals. A second, more surgical experiment, knocking out a gene called Wdfy4 that cDC1s need specifically for cross-presentation, produced the same protective effect, which narrows the explanation to that one antigen-handling trick rather than to cDC1s’ other jobs.

David Holtzman, the study’s senior author, said the appeal of a target outside the brain is as practical as it is scientific: “One of the issues in developing treatments for neurological diseases is that you need to engineer your treatment so that it gets into the brain and past the blood-brain barrier, but we might not actually need to get the drugs into the central nervous system to mitigate neurodegeneration.” There are lots of ways to manipulate T cells that have already been studied extensively and approved as treatments for other diseases, he added, and many of them have not yet been tried against neurodegenerative disease.

Tracking Down Where the Priming Happens

To find out physically where the priming happens, the team turned to a stand-in antigen, ovalbumin, loading it onto cells and injecting those cells directly into the brains of mice carrying antigen-specific T cells that divide, and glow under a tracking dye, whenever they recognize their target. Those tracer T cells almost never divided if they stayed in the meninges or brain tissue itself. They proliferated instead in the lymph nodes draining the brain, and to a lesser extent the spleen, but only in mice that still had functioning cDC1s. The same pattern held with a more realistic antigen source: cultured neurons engineered to display the marker protein, injected straight into the brain. Even then, priming happened in the draining lymph nodes, not on site, which fits a route where injured neurons shed material that drains, through a network of lymphatic vessels in the tissue surrounding the brain, into the neck lymph nodes and lands in front of a waiting dendritic cell. Mass spectrometry of the molecules displayed on brain cells from 50 TE4 mice and 60 non-tau control mice turned up candidate fragments from tau itself, along with two other neuron-associated proteins, stathmin-3 and neurofilament light, though which of these, if any, the T cells are actually responding to is still unknown.

None of this was tested as a treatment given after disease had already set in. The cDC1-deficient mice lacked those cells from birth, and the authors say the harder question, whether blocking the pathway partway through life works as well as blocking it from the start, is still open. The dendritic cells themselves did not budge with normal aging, in mice or in blood samples from people spanning five decades of adulthood, so age-related decline in the cells is not the explanation for why this pathway becomes more damaging later in life.

The human side of the study is suggestive rather than proven. Postmortem brain tissue from people with progressive supranuclear palsy, Pick’s disease, and corticobasal degeneration showed the same CD8 T cell buildup seen in the mice, but nobody has yet shown that human cDC1s are doing the priming; cerebrospinal fluid and meningeal dendritic cells from people with Alzheimer’s disease or mild cognitive impairment looked no different from those of healthy people, which the authors read as reassuring, since the cells stay poised to act, rather than as evidence against the pathway.

If the human pathway mirrors the mouse one, the meningeal lymphatic system, the drainage route connecting brain and neck lymph nodes, becomes a lever with two edges. Blocking it entirely has, in other studies, made things worse in models of amyloid disease, chronic stress, and aging, while boosting lymphatic drainage has improved brain perfusion and memory in old mice. That leaves a narrower kind of target: something that interrupts T cell priming specifically, without shutting down the drainage the brain also depends on to clear its own waste. T cells manipulated in exactly this way already exist as approved drugs for other diseases, which is the gap Holtzman’s team is now trying to close for neurodegeneration specifically.

The next experiments will test whether switching off cDC1 priming partway through a mouse’s life, once tau pathology has already started, still holds off the damage the way removing the cells from birth did. If it does, the fight against Alzheimer’s-like neurodegeneration may end up being waged less in the brain than in the unglamorous lymph nodes a few inches away.

FAQ